Joint Purification Systems Inc. announced today that it has closed a $7.8 million Series A financing.
SOLANA BEACH, CALIF. (PRWEB) APRIL 18, 2018
Joint Purification Systems Inc. (JPS), an early stage medical device company developing novel combination products to treat chronic peri-prosthetic joint infection (PJI), announced today that it has closed a $7.8 million Series A financing. The financing was led by Johnson & Johnson Innovation – JJDC, Inc. MedVest Fund II was also a new investor in the round. Proceeds will be used for preparation of the company’s first products in the X7 Spacer System for initiation of human clinical studies.